Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma

JAMA Dermatology

Volumn 149, Issue 12, 2013, Pages 1403-1406

  Busser, Benoit ^a   Leccia, Marie Therese ^a   Gras Combe, Guillaume ^a   Bricault, Ivan ^a   Templier, Isabelle ^a   Claeys, Antoine ^a   Richard, Marie Jeanne ^a   De Fraipont, Florence ^a   Charles, Julie ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; VEMURAFENIB;

ADULT; ARTICLE; BRAF GENE; BRAIN METASTASIS; CASE REPORT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; KERATOACANTHOMA; MALE; MEDICAL HISTORY; MELANOMA; MELANOMA METASTASIS; METASTASIS; MIDDLE AGED; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; NAUSEA; ONCOGENE; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PYROSEQUENCING; SEQUENCE ANALYSIS; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

EID: 84892182925     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.8198     Document Type: Article

References (15)

1. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
2. Wellcome Trust Sanger Institute. Catalogue of Somatic Mutations in Cancer. http://cancer.sanger .ac.uk/cancergenome/projects/cosmic/. Accessed September 10, 2013.
3. Rubinstein JC, Sznol M, Pavlick AC, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med. 2010;8:67.
4. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199- 6206.
5. Dufort S, RichardMJ, de Fraipont F. Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Anal Biochem. 2009;391(2):166-168.
6. Dufort S, RichardMJ, Lantuejoul S, de Fraipont F. Pyrosequencing, amethod approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. J Exp Clin Cancer Res. 2011;30:57.
7. Forbes SA, Bindal N, Bamford S, et al. COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39(Database issue):D945-D950.
8. Sinha R, Edmonds K, Newton-Bishop JA, Gore ME, Larkin J, Fearfield L. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: Practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol. 2012;167(5):987-994.
9. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596-599.
10. Wan PT, Garnett MJ, Roe SM, et al Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855-867.
11. Reifenberger J, Knobbe CB, Sterzinger AA, et al. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer. 2004;109(3):377-384.
12. Trovisco V, Soares P, Soares R,Magalhães J, Sá-Couto P, Sobrinho-SimõesM. A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol. 2005;36(6):694-697.
13. Hou P, Liu D, XingM. Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle. 2007;6(3):377-379.
14. Dhillon AS, KolchW. Oncogenic B-Raf mutations: Crystal clear at last. Cancer Cell. 2004;5(4):303-304.
15. Barzon L, Masi G, Boschin IM, et al. Characterization of a novel complex BRAF mutation in a follicular variant papillary thyroid carcinoma. Eur J Endocrinol. 2008;159(1):77-80.